You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePazopanib
Accession NumberDB06589
TypeSmall Molecule
GroupsApproved
DescriptionPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Structure
Thumb
Synonyms
GW 78603
GW786034
Pazopanibum
External Identifiers
  • GW-786034
  • GW786034
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Votrienttablet, film coated200 mg/1oralGlaxo Smith Kline Llc2009-10-19Not applicableUs
VotrientFilm-coated tablet200 mgOral useNovartis Europharm Limited  2010-06-14Not applicableEu
Votrienttablet200 mgoralNovartis Pharmaceuticals Canada Inc2010-08-13Not applicableCanada
VotrientFilm-coated tablet400 mgOral useNovartis Europharm Limited  2010-06-14Not applicableEu
Votrienttablet400 mgoralNovartis Pharmaceuticals Canada IncNot applicableNot applicableCanada
VotrientFilm-coated tablet400 mgOral useNovartis Europharm Limited  2010-06-14Not applicableEu
VotrientFilm-coated tablet200 mgOral useNovartis Europharm Limited  2010-06-14Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pazopanib Hydrochloride
Thumb
  • InChI Key: MQHIQUBXFFAOMK-UHFFFAOYSA-N
  • Monoisotopic Mass: 473.140071444
  • Average Mass: 473.979
DBSALT000135
Categories
UNII7RN5DR86CK
CAS number444731-52-6
WeightAverage: 437.518
Monoisotopic: 437.163393705
Chemical FormulaC21H23N7O2S
InChI KeyInChIKey=CUIHSIWYWATEQL-UHFFFAOYSA-N
InChI
InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
IUPAC Name
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide
SMILES
CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassTertiary amines
Direct ParentAlkyldiarylamines
Alternative Parents
Substituents
  • Alkyldiarylamine
  • Benzenesulfonamide
  • Indazole
  • Benzopyrazole
  • Aminotoluene
  • Toluene
  • Aminopyrimidine
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationTreatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
PharmacodynamicsPazopanib is a synthetic indazolylpyrimidine and reaches steady state concentrations of >15 μg/ml. This concentration is high enough to observe maximal inhibition of VEGFR2 phosphorylation and some anti-tumour activity (concentration required to inhibit receptors is 0.01 - 0.084 μmol/L). A reduction in tumour blood flow, increased tumour apoptosis, inhibition of tumour growth, reduction in tumour interstitial fluid pressure, and hypoxia in cancer cells can be observed in patients receiving treatment.
Mechanism of actionPazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth.
Related Articles
AbsorptionAbsorption of pazopanib in cancer patients is slow and incomplete. In patients with solid tumour, over a dose range of 50-2000 mg, absorption is nonlinear. Significant accumulation of pazopanib can also be observed in patients receiving 800 mg once daily for 22 days. Crushing tablets may increase exposure (increase in Cmax and AUC, while Tmax decreases by 2 hours). Bioavailability, oral tablet 800 mg, cancer patient = 21%; Bioavailability may be low due to incomplete absorption from the gastrointestinal tract. The major circulating component of the drug in the systemic is pazopanib, and not its metabolites. Mean maximum plasma concentration= 58.1 µg/mL; Mean AUC= 1037 µg · h/mL;
Volume of distribution

Vd steady state, IV administration 5 mg, cancer patient = 11.1 L (range of 9.15 – 13.4)

Protein binding>99% protein bound, independent of concentrations over a range of 10-100 μg/mL.
Metabolism

Metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8. Metabolites are less active than pazopanib (10 to 20-fold less active). Three of its metabolites can be observed in the systemic and account for <10% of plasma radioactivity.

Route of eliminationPrimarily excreted via feces (82.2%) and to a negligible extent via urine (<4%) in cancer patients. Most of the administered dose is excreted unchanged. Approximately 10% of dose are oxidative metabolites and are mostly eliminated via the feces.
Half life35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.
Clearance

CL, cancer patient, IV administration 5 mg = 4mL/min
Half of the absorbed dose is cleared via oxidative metabolism.

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8788
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.8307
P-glycoprotein inhibitor INon-inhibitor0.8126
P-glycoprotein inhibitor IIInhibitor0.5
Renal organic cation transporterNon-inhibitor0.8152
CYP450 2C9 substrateNon-substrate0.7797
CYP450 2D6 substrateNon-substrate0.8008
CYP450 3A4 substrateNon-substrate0.6024
CYP450 1A2 substrateNon-inhibitor0.5
CYP450 2C9 inhibitorNon-inhibitor0.5065
CYP450 2D6 inhibitorNon-inhibitor0.7779
CYP450 2C19 inhibitorNon-inhibitor0.6811
CYP450 3A4 inhibitorNon-inhibitor0.5385
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5668
Ames testNon AMES toxic0.6543
CarcinogenicityNon-carcinogens0.8567
BiodegradationNot ready biodegradable0.9935
Rat acute toxicity2.3961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9219
hERG inhibition (predictor II)Non-inhibitor0.7129
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Film-coated tabletOral use200 mg
Film-coated tabletOral use400 mg
Tabletoral200 mg
Tabletoral400 mg
Tablet, film coatedoral200 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7105530 No2003-10-192023-10-19Us
US7262203 No2001-12-192021-12-19Us
US8114885 No2001-12-192021-12-19Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0433 mg/mLALOGPS
logP3.59ALOGPS
logP3.55ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)10.41ChemAxon
pKa (Strongest Basic)5.07ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area119.03 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity132.18 m3·mol-1ChemAxon
Polarizability45.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Sonpavde G, Hutson TE, Sternberg CN: Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253. [PubMed:18230058 ]
  2. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774 ]
  3. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165 ]
  4. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
External Links
ATC CodesL01XE11
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (593 KB)
MSDSDownload (70.4 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Pazopanib can be increased when it is combined with Abiraterone.
AcetaminophenThe serum concentration of Pazopanib can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pazopanib.
AfatinibThe serum concentration of Pazopanib can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Pazopanib can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Pazopanib can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Pazopanib can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Pazopanib can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Pazopanib.
Aluminum hydroxideThe serum concentration of Pazopanib can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Pazopanib can be decreased when it is combined with Aluminum phosphate.
AmantadineThe serum concentration of Pazopanib can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Pazopanib can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Pazopanib can be increased when it is combined with Amiodarone.
AmiodaronePazopanib may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe serum concentration of Pazopanib can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Pazopanib can be increased when it is combined with Amlodipine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Pazopanib.
AmprenavirThe serum concentration of Pazopanib can be increased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Pazopanib can be increased when it is combined with Amsacrine.
AnagrelidePazopanib may increase the QTc-prolonging activities of Anagrelide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Pazopanib.
AprepitantThe serum concentration of Pazopanib can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Pazopanib.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Pazopanib.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Pazopanib.
Arsenic trioxidePazopanib may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherPazopanib may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Pazopanib can be decreased when combined with Artemether.
AsenapineThe serum concentration of Pazopanib can be decreased when it is combined with Asenapine.
AsenapinePazopanib may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Pazopanib can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Pazopanib can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Pazopanib can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Pazopanib.
AtorvastatinThe serum concentration of Pazopanib can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Pazopanib can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Pazopanib can be increased when it is combined with Azithromycin.
AzithromycinPazopanib may increase the QTc-prolonging activities of Azithromycin.
BedaquilinePazopanib may increase the QTc-prolonging activities of Bedaquiline.
BenzocaineThe serum concentration of Pazopanib can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Pazopanib can be increased when it is combined with Bepridil.
BetaxololThe metabolism of Pazopanib can be decreased when combined with Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Pazopanib.
BexaroteneThe serum concentration of Pazopanib can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Pazopanib can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe serum concentration of Pazopanib can be decreased when it is combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Pazopanib can be increased when it is combined with Boceprevir.
BortezomibBortezomib may increase the QTc-prolonging activities of Pazopanib.
BosentanThe serum concentration of Pazopanib can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Pazopanib can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Pazopanib can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Pazopanib can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Pazopanib can be decreased when combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Pazopanib.
BuspironeThe serum concentration of Pazopanib can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Pazopanib can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Pazopanib can be increased when it is combined with Caffeine.
Calcium carbonateThe serum concentration of Pazopanib can be decreased when it is combined with Calcium carbonate.
CanagliflozinThe serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Pazopanib can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Pazopanib can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Pazopanib can be increased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Pazopanib can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Pazopanib can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Pazopanib can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Pazopanib can be increased when it is combined with Ceritinib.
CeritinibPazopanib may increase the QTc-prolonging activities of Ceritinib.
CerivastatinCerivastatin may increase the hepatotoxic activities of Pazopanib.
ChloroquineThe serum concentration of Pazopanib can be increased when it is combined with Chloroquine.
ChloroquinePazopanib may increase the QTc-prolonging activities of Chloroquine.
ChlorpromazineThe serum concentration of Pazopanib can be increased when it is combined with Chlorpromazine.
ChlorpromazinePazopanib may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideThe serum concentration of Pazopanib can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Pazopanib can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Pazopanib can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Pazopanib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Pazopanib can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Pazopanib can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Pazopanib can be increased when it is combined with Cimetidine.
CinacalcetThe metabolism of Pazopanib can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Pazopanib can be increased when it is combined with Ciprofloxacin.
CiprofloxacinPazopanib may increase the QTc-prolonging activities of Ciprofloxacin.
CisapridePazopanib may increase the QTc-prolonging activities of Cisapride.
CitalopramThe serum concentration of Pazopanib can be increased when it is combined with Citalopram.
CitalopramPazopanib may increase the QTc-prolonging activities of Citalopram.
ClarithromycinThe serum concentration of Pazopanib can be increased when it is combined with Clarithromycin.
ClarithromycinPazopanib may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Pazopanib can be decreased when combined with Clemastine.
ClobazamThe metabolism of Pazopanib can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Pazopanib can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Pazopanib can be increased when it is combined with Clomipramine.
ClopidogrelThe metabolism of Pazopanib can be decreased when combined with Clopidogrel.
ClotrimazoleThe serum concentration of Pazopanib can be increased when it is combined with Clotrimazole.
ClozapinePazopanib may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Pazopanib can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Pazopanib can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Pazopanib can be decreased when combined with Cocaine.
Coenzyme Q10Coenzyme Q10 may increase the hepatotoxic activities of Pazopanib.
ColchicineThe serum concentration of Pazopanib can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Pazopanib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Pazopanib can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Pazopanib can be increased when it is combined with Crizotinib.
CrizotinibPazopanib may increase the QTc-prolonging activities of Crizotinib.
CyclophosphamideThe serum concentration of Pazopanib can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Pazopanib can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Pazopanib can be increased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Pazopanib can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Pazopanib can be increased when it is combined with Dactinomycin.
DaidzinThe serum concentration of Pazopanib can be increased when it is combined with Daidzin.
DarifenacinThe metabolism of Pazopanib can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Pazopanib can be increased when it is combined with Darunavir.
DasabuvirThe serum concentration of Pazopanib can be increased when it is combined with Dasabuvir.
DasatinibThe serum concentration of Pazopanib can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Pazopanib can be increased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Pazopanib can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Pazopanib.
DelavirdineThe metabolism of Pazopanib can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pazopanib.
DesfluraneDesflurane may increase the QTc-prolonging activities of Pazopanib.
DesipramineThe serum concentration of Pazopanib can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pazopanib.
DesloratadineThe serum concentration of Pazopanib can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Pazopanib can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Pazopanib can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Pazopanib can be increased when it is combined with Diethylstilbestrol.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pazopanib.
DigoxinThe serum concentration of Pazopanib can be increased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Pazopanib can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Pazopanib can be increased when it is combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Pazopanib.
DipyridamoleThe serum concentration of Pazopanib can be increased when it is combined with Dipyridamole.
DisopyramidePazopanib may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.
DofetilidePazopanib may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Pazopanib.
DomperidonePazopanib may increase the QTc-prolonging activities of Domperidone.
DoxazosinThe serum concentration of Pazopanib can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Pazopanib can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Pazopanib can be increased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Pazopanib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Pazopanib can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Pazopanib can be increased when it is combined with Dronedarone.
DronedaronePazopanib may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Pazopanib.
DuloxetineThe metabolism of Pazopanib can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Pazopanib can be decreased when it is combined with Efavirenz.
ElacridarThe serum concentration of Pazopanib can be increased when it is combined with Elacridar.
ElbasvirThe serum concentration of Pazopanib can be increased when it is combined with Elbasvir.
EliglustatPazopanib may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Pazopanib can be decreased when combined with Eliglustat.
EltrombopagThe serum concentration of Pazopanib can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Pazopanib can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Pazopanib can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Pazopanib can be decreased when it is combined with Epinastine.
ErgonovineThe serum concentration of Pazopanib can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Pazopanib can be increased when it is combined with Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Pazopanib.
ErlotinibThe serum concentration of Pazopanib can be increased when it is combined with Erlotinib.
ErythromycinThe serum concentration of Pazopanib can be increased when it is combined with Erythromycin.
ErythromycinPazopanib may increase the QTc-prolonging activities of Erythromycin.
EscitalopramPazopanib may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Pazopanib can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Pazopanib can be decreased when it is combined with Esomeprazole.
EstradiolThe serum concentration of Pazopanib can be increased when it is combined with Estradiol.
EstramustineThe serum concentration of Pazopanib can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Pazopanib can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Pazopanib can be increased when it is combined with Estrone.
EtoposideThe serum concentration of Pazopanib can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Pazopanib can be increased when it is combined with Etravirine.
EzogabineEzogabine may increase the QTc-prolonging activities of Pazopanib.
FamotidineThe serum concentration of Pazopanib can be decreased when it is combined with Famotidine.
FelbamateFelbamate may increase the QTc-prolonging activities of Pazopanib.
FelodipineThe serum concentration of Pazopanib can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Pazopanib can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Pazopanib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Pazopanib can be increased when it is combined with Fidaxomicin.
FingolimodPazopanib may increase the immunosuppressive activities of Fingolimod.
FingolimodFingolimod may increase the QTc-prolonging activities of Pazopanib.
FlecainideFlecainide may increase the QTc-prolonging activities of Pazopanib.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Pazopanib.
FluconazoleThe serum concentration of Pazopanib can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.
FluoxetinePazopanib may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolThe serum concentration of Pazopanib can be increased when it is combined with Flupentixol.
FlupentixolPazopanib may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Pazopanib can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Pazopanib can be increased when it is combined with Flurazepam.
FluvastatinFluvastatin may increase the hepatotoxic activities of Pazopanib.
FluvoxamineThe serum concentration of Pazopanib can be increased when it is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Pazopanib.
FosamprenavirThe metabolism of Pazopanib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pazopanib can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Pazopanib.
FosphenytoinThe serum concentration of Pazopanib can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Pazopanib can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Pazopanib.
GalantamineGalantamine may increase the QTc-prolonging activities of Pazopanib.
GefitinibThe serum concentration of Pazopanib can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Pazopanib can be decreased when combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Pazopanib.
GenisteinThe serum concentration of Pazopanib can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Pazopanib can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Pazopanib can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Pazopanib.
Gramicidin DThe serum concentration of Pazopanib can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Pazopanib.
GrepafloxacinThe serum concentration of Pazopanib can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Pazopanib can be increased when it is combined with Haloperidol.
HaloperidolPazopanib may increase the QTc-prolonging activities of Haloperidol.
HesperetinThe serum concentration of Pazopanib can be increased when it is combined with Hesperetin.
HistrelinHistrelin may increase the QTc-prolonging activities of Pazopanib.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Pazopanib.
HydrocortisoneThe serum concentration of Pazopanib can be increased when it is combined with Hydrocortisone.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Pazopanib.
IbandronateIbandronate may increase the QTc-prolonging activities of Pazopanib.
IbutilidePazopanib may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Pazopanib can be increased when it is combined with Idelalisib.
IloperidonePazopanib may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Pazopanib can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Pazopanib can be increased when it is combined with Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Pazopanib.
IndapamideIndapamide may increase the QTc-prolonging activities of Pazopanib.
IndinavirThe serum concentration of Pazopanib can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Pazopanib can be increased when it is combined with Indomethacin.
IrbesartanThe metabolism of Pazopanib can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Pazopanib.
IsavuconazoniumThe serum concentration of Pazopanib can be increased when it is combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Pazopanib.
IsoniazidThe metabolism of Pazopanib can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Pazopanib.
ItraconazoleThe serum concentration of Pazopanib can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Pazopanib.
IvacaftorThe serum concentration of Pazopanib can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Pazopanib can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Pazopanib can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Pazopanib can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Pazopanib can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Pazopanib can be increased when it is combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Pazopanib is combined with Leflunomide.
LenvatinibPazopanib may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Pazopanib.
LevofloxacinThe serum concentration of Pazopanib can be increased when it is combined with Levofloxacin.
LevofloxacinPazopanib may increase the QTc-prolonging activities of Levofloxacin.
LevothyroxineThe serum concentration of Pazopanib can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Pazopanib can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Pazopanib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Pazopanib can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Pazopanib can be increased when it is combined with Lisinopril.
LithiumLithium may increase the QTc-prolonging activities of Pazopanib.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Pazopanib.
LoperamideThe serum concentration of Pazopanib can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Pazopanib can be increased when it is combined with Lopinavir.
LopinavirPazopanib may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Pazopanib can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Pazopanib can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Pazopanib can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Pazopanib can be increased when it is combined with Lovastatin.
LuliconazoleThe serum concentration of Pazopanib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Pazopanib can be decreased when it is combined with Lumacaftor.
LumefantrinePazopanib may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Pazopanib can be decreased when combined with Lumefantrine.
MagaldrateThe serum concentration of Pazopanib can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.
Magnesium TrisilicateThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium Trisilicate.
MaprotilineThe serum concentration of Pazopanib can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Pazopanib can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Pazopanib can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Pazopanib can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Pazopanib can be increased when it is combined with Meprobamate.
MethadoneThe serum concentration of Pazopanib can be increased when it is combined with Methadone.
MethadonePazopanib may increase the QTc-prolonging activities of Methadone.
MethanthelineThe serum concentration of Pazopanib can be decreased when it is combined with Methantheline.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Pazopanib.
MetiamideThe serum concentration of Pazopanib can be decreased when it is combined with Metiamide.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Pazopanib.
MetoprololThe serum concentration of Pazopanib can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Pazopanib.
MevastatinMevastatin may increase the hepatotoxic activities of Pazopanib.
MexiletineThe metabolism of Pazopanib can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Pazopanib can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Pazopanib can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Pazopanib can be increased when it is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Pazopanib.
MirabegronMirabegron may increase the QTc-prolonging activities of Pazopanib.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Pazopanib.
MitomycinThe serum concentration of Pazopanib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Pazopanib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Pazopanib can be increased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Pazopanib can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Pazopanib.
MorphineThe serum concentration of Pazopanib can be increased when it is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Pazopanib.
NafcillinThe serum concentration of Pazopanib can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Pazopanib can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Pazopanib can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.
NefazodoneThe serum concentration of Pazopanib can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Pazopanib can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Pazopanib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Pazopanib can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Pazopanib can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Pazopanib can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Pazopanib can be increased when it is combined with Nifedipine.
NilotinibThe serum concentration of Pazopanib can be increased when it is combined with Nilotinib.
NilotinibPazopanib may increase the QTc-prolonging activities of Nilotinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Pazopanib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Pazopanib.
NisoldipineThe serum concentration of Pazopanib can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Pazopanib can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Pazopanib can be decreased when it is combined with Nizatidine.
NorethisteroneThe serum concentration of Pazopanib can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Pazopanib.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Pazopanib.
NovobiocinThe serum concentration of Pazopanib can be increased when it is combined with Novobiocin.
OctreotideOctreotide may increase the QTc-prolonging activities of Pazopanib.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Pazopanib.
OlanzapineThe serum concentration of Pazopanib can be decreased when it is combined with Olanzapine.
OlaparibThe metabolism of Pazopanib can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Pazopanib.
OmeprazoleThe serum concentration of Pazopanib can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Pazopanib.
OsimertinibThe serum concentration of Pazopanib can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Pazopanib.
OxytocinOxytocin may increase the QTc-prolonging activities of Pazopanib.
P-NitrophenolThe serum concentration of Pazopanib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Pazopanib can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Pazopanib can be increased when it is combined with Palbociclib.
PaliperidonePazopanib may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Pazopanib can be increased when it is combined with Palmitic Acid.
PanobinostatPazopanib may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Pazopanib can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Pazopanib can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Pazopanib can be increased when it is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Pazopanib can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Pazopanib.
PentobarbitalThe serum concentration of Pazopanib can be decreased when it is combined with Pentobarbital.
PerflutrenPerflutren may increase the QTc-prolonging activities of Pazopanib.
PerindoprilThe serum concentration of Pazopanib can be increased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Pazopanib can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Pazopanib can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pazopanib.
PimozideThe serum concentration of Pazopanib can be increased when it is combined with Pimozide.
PioglitazoneThe metabolism of Pazopanib can be decreased when combined with Pioglitazone.
PitavastatinPitavastatin may increase the hepatotoxic activities of Pazopanib.
Platelet Activating FactorThe serum concentration of Pazopanib can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Pazopanib can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Pazopanib can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Pazopanib can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Pazopanib can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Pazopanib can be increased when it is combined with Prednisone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Pazopanib.
PrimidoneThe serum concentration of Pazopanib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Pazopanib can be increased when it is combined with Probenecid.
ProcainamidePazopanib may increase the QTc-prolonging activities of Procainamide.
ProgesteroneThe serum concentration of Pazopanib can be increased when it is combined with Progesterone.
PromazinePazopanib may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Pazopanib can be decreased when combined with Promazine.
PromethazineThe serum concentration of Pazopanib can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Pazopanib can be increased when it is combined with Propafenone.
PropafenonePazopanib may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Pazopanib.
PropranololThe serum concentration of Pazopanib can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Pazopanib can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Pazopanib can be increased when it is combined with Quercetin.
QuetiapinePazopanib may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Pazopanib can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Pazopanib can be increased when it is combined with Quinidine.
QuinidinePazopanib may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Pazopanib can be increased when it is combined with Quinine.
QuininePazopanib may increase the QTc-prolonging activities of Quinine.
RabeprazoleThe serum concentration of Pazopanib can be increased when it is combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Pazopanib is combined with Rabies vaccine.
RanitidineThe serum concentration of Pazopanib can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Pazopanib can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Pazopanib can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Pazopanib can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Pazopanib can be increased when it is combined with Reserpine.
RifabutinThe serum concentration of Pazopanib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Pazopanib can be increased when it is combined with Rifampicin.
RifapentineThe serum concentration of Pazopanib can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Pazopanib can be increased when it is combined with Rilpivirine.
RisperidoneRisperidone may increase the QTc-prolonging activities of Pazopanib.
RitonavirThe serum concentration of Pazopanib can be increased when it is combined with Ritonavir.
RoflumilastRoflumilast may increase the immunosuppressive activities of Pazopanib.
RolapitantThe serum concentration of Pazopanib can be increased when it is combined with Rolapitant.
RopiniroleThe metabolism of Pazopanib can be decreased when combined with Ropinirole.
RosiglitazoneThe metabolism of Pazopanib can be decreased when combined with Rosiglitazone.
RosuvastatinRosuvastatin may increase the hepatotoxic activities of Pazopanib.
Roxatidine acetateThe serum concentration of Pazopanib can be decreased when it is combined with Roxatidine acetate.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Pazopanib.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Pazopanib.
SaquinavirThe serum concentration of Pazopanib can be increased when it is combined with Saquinavir.
SaquinavirPazopanib may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe serum concentration of Pazopanib can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Pazopanib can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Pazopanib can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Pazopanib can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Pazopanib.
SildenafilThe metabolism of Pazopanib can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Pazopanib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pazopanib can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Pazopanib can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pazopanib.
SirolimusThe serum concentration of Pazopanib can be increased when it is combined with Sirolimus.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Pazopanib.
SorafenibThe serum concentration of Pazopanib can be increased when it is combined with Sorafenib.
SotalolPazopanib may increase the QTc-prolonging activities of Sotalol.
SpironolactoneThe serum concentration of Pazopanib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Pazopanib can be decreased when it is combined with St. John&#39;s Wort.
StaurosporineThe serum concentration of Pazopanib can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Pazopanib can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Pazopanib can be decreased when it is combined with Streptozocin.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Pazopanib.
SulfasalazineThe serum concentration of Pazopanib can be increased when it is combined with Sulfasalazine.
SulfinpyrazoneThe serum concentration of Pazopanib can be increased when it is combined with Sulfinpyrazone.
SulfisoxazolePazopanib may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Pazopanib can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Pazopanib can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Pazopanib can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Pazopanib can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pazopanib.
TAK-390MRThe serum concentration of Pazopanib can be decreased when it is combined with TAK-390MR.
TamoxifenThe serum concentration of Pazopanib can be increased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Pazopanib can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Pazopanib can be increased when it is combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Pazopanib.
TelithromycinThe serum concentration of Pazopanib can be increased when it is combined with Telithromycin.
TelithromycinPazopanib may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe serum concentration of Pazopanib can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Pazopanib can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Pazopanib can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Pazopanib can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Pazopanib can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Pazopanib.
TerfenadineThe serum concentration of Pazopanib can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Pazopanib can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Pazopanib can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Pazopanib can be increased when it is combined with Testosterone.
TetrabenazinePazopanib may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe metabolism of Pazopanib can be decreased when combined with Theophylline.
ThioridazinePazopanib may increase the QTc-prolonging activities of Thioridazine.
ThioridazineThe metabolism of Pazopanib can be decreased when combined with Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Pazopanib.
TicagrelorThe serum concentration of Pazopanib can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Pazopanib can be decreased when combined with Ticlopidine.
TipranavirThe metabolism of Pazopanib can be decreased when combined with Tipranavir.
TizanidineTizanidine may increase the QTc-prolonging activities of Pazopanib.
TocilizumabThe serum concentration of Pazopanib can be decreased when it is combined with Tocilizumab.
TofacitinibPazopanib may increase the immunosuppressive activities of Tofacitinib.
TolterodineTolterodine may increase the QTc-prolonging activities of Pazopanib.
TolvaptanThe serum concentration of Pazopanib can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Pazopanib can be increased when it is combined with Topotecan.
ToremifenePazopanib may increase the QTc-prolonging activities of Toremifene.
TranylcypromineThe metabolism of Pazopanib can be decreased when combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the neutropenic activities of Pazopanib.
TrazodoneTrazodone may increase the QTc-prolonging activities of Pazopanib.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Pazopanib.
TrifluoperazineThe serum concentration of Pazopanib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Pazopanib can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Pazopanib can be increased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Pazopanib can be increased when it is combined with Trimipramine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Pazopanib.
TroleandomycinThe serum concentration of Pazopanib can be increased when it is combined with Troleandomycin.
VandetanibThe serum concentration of Pazopanib can be increased when it is combined with Vandetanib.
VandetanibPazopanib may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Pazopanib.
VemurafenibThe serum concentration of Pazopanib can be increased when it is combined with Vemurafenib.
VemurafenibPazopanib may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Pazopanib can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Pazopanib can be increased when it is combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Pazopanib.
VinblastineThe serum concentration of Pazopanib can be increased when it is combined with Vinblastine.
VincristineThe serum concentration of Pazopanib can be increased when it is combined with Vincristine.
VinorelbineThe serum concentration of Pazopanib can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Pazopanib can be increased when it is combined with Vismodegib.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Pazopanib.
VorinostatVorinostat may increase the QTc-prolonging activities of Pazopanib.
ZimelidineThe serum concentration of Pazopanib can be increased when it is combined with Zimelidine.
ZiprasidonePazopanib may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Pazopanib can be decreased when combined with Ziprasidone.
ZuclopenthixolPazopanib may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid drinking grapefruit juice as it is a CYP 3A4 inhibitor and will increase exposure of pazopanib
  • Bioavailability increases with food. Take pazopanib on empty stomach.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vegf-b-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation ...
Gene Name:
FLT1
Uniprot ID:
P17948
Molecular Weight:
150767.185 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domai...
Gene Name:
KDR
Uniprot ID:
P35968
Molecular Weight:
151525.555 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced pr...
Gene Name:
FLT4
Uniprot ID:
P35916
Molecular Weight:
152755.94 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for...
Gene Name:
PDGFRA
Uniprot ID:
P16234
Molecular Weight:
122668.46 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor binding
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:
PDGFRB
Uniprot ID:
P09619
Molecular Weight:
123966.895 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineraliz...
Gene Name:
FGFR3
Uniprot ID:
P22607
Molecular Weight:
87708.905 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Non-membrane spanning protein tyrosine kinase activity
Specific Function:
Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR recepto...
Gene Name:
ITK
Uniprot ID:
Q08881
Molecular Weight:
71830.405 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
S100 protein binding
Specific Function:
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:
FGF1
Uniprot ID:
P05230
Molecular Weight:
17459.58 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Signaling adaptor activity
Specific Function:
Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase.
Gene Name:
SH2B3
Uniprot ID:
Q9UQQ2
Molecular Weight:
63224.45 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357 ]
  2. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD: An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Nov;88(5):652-9. doi: 10.1038/clpt.2010.158. Epub 2010 Sep 29. [PubMed:20881954 ]
  3. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357 ]
  2. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD: An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Nov;88(5):652-9. doi: 10.1038/clpt.2010.158. Epub 2010 Sep 29. [PubMed:20881954 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357 ]
  2. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:38 / Updated on September 25, 2016 02:16